CBPO:NSD-China Biologic Products Holdings, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 118.99

Change

+0.04 (+0.03)%

Market Cap

USD 4.61B

Volume

0.21M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

China Biologic Products Holdings, Inc. engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia. The company also provides human immunoglobulin and IVIG for original and secondary immunoglobulin deficiency, auto-immune deficiency, and immunoglobulin G secondary deficiency; human hepatitis B immunoglobulin for the prevention of measles and contagious hepatitis; human rabies immunoglobulin primarily for passive immunity from bites or claws by rabies or other infected animals; and human tetanus immunoglobulin for the prevention and therapy of tetanus. In addition, it offers placenta polypeptide for the treatment of cell immunity deficiency diseases, viral infection, and leucopenia, as well as assists in postoperative healing; factor VIII for treating coagulopathies; human fibrinogen; and human prothrombin complex concentrate for treating congenital and acquired clotting factor II, VII, IX, X deficiency, as well as excessive anticoagulant, vitamin K deficiency, etc. Further, the company is developing Human fibrinogen for the treatment for lack of fibrinogen and increase human fibrinogen concentration; and artificial dura and spinal dura mater products for use in brain and spinal surgeries. The company sells its products directly, as well as through distributors. The company was formerly known as China Biologic Products, Inc. and changed its name to China Biologic Products Holdings, Inc. in July 2017. China Biologic Products Holdings, Inc. is headquartered in Beijing, the People's Republic of China. Address: Jialong International Tower, Beijing, China, 100125

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-11-30 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+1.04 (+0.46%)

USD58.95B 22.22 17.39
REGN Regeneron Pharmaceuticals, Inc

+1.98 (+0.39%)

USD54.85B 18.84 14.53
MRNA Moderna, Inc

+25.71 (+20.24%)

USD50.27B N/A N/A
SGEN Seagen Inc

+1.19 (+0.70%)

USD30.27B 63.87 62.62
ALXN Alexion Pharmaceuticals, Inc

-1.72 (-1.39%)

USD27.10B 28.74 26.92
BNTX BioNTech SE

+14.25 (+12.96%)

USD26.48B -99,999.99 N/A
RPRX Royalty Pharma plc

+1.00 (+2.40%)

USD26.01B 22.60 9.74
GMAB Genmab A/S

+1.48 (+3.99%)

USD24.32B 26.59 2.61
BGNE BeiGene, Ltd

-30.20 (-10.56%)

USD24.20B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing CBPO

Symbol Name Weight Mer Price(Change) Market Cap
VVO:CA Vanguard Global Minimum V.. 0.00 % 0.40 %

-0.34 (-1.07%)

USD0.06B
VMVL:LSE Vanguard Global Minimum V.. 0.00 % 0.00 %

-0.27 (-1.04%)

USD0.05B
VMVL:XETRA Vanguard Global Minimum V.. 0.00 % 0.00 %

-0.24 (-0.81%)

USD0.05B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.24% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.24% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 2.02% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.02% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 0.11% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.11% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 1.74% N/A N/A 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 1.74% N/A N/A 38% F
Risk Return Profile  
Volatility (Standard Deviation) 24.12% N/A N/A 61% D-
Risk Adjusted Return 7.23% N/A N/A 37% F
Market Capitalization 4.61B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 33.33 N/A N/A N/A N/A
Price/Book Ratio 2.45 N/A N/A N/A N/A
Price / Cash Flow Ratio 20.12 N/A N/A N/A N/A
EV/EBITDA 15.54 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 8.94% N/A N/A N/A N/A
Return on Invested Capital 7.93% N/A N/A N/A N/A
Return on Assets 5.62% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.59 N/A N/A N/A N/A
Short Percent 2.32% N/A N/A N/A N/A
Beta 0.45 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike